Direct answer

Patients should disclose cannabis and cannabinoid use, including smoking, vaping, edibles, concentrates, CBD, and prescribed products. Elective surgery should be postponed when acute intoxication impairs decision-making. Current perioperative guidance recommends delaying elective surgery for at least two hours after cannabis smoking, while heavier or chronic use may require additional individualized planning.

Key takeaways

  • Acute intoxication can invalidate informed consent and increase anxiety, paranoia, tachycardia, or hemodynamic instability.
  • Smoked or vaped cannabis can affect airway resistance and cardiovascular risk around anesthesia.
  • Frequent users may require different anesthetic doses and may experience more postoperative pain or opioid requirements.
  • Cannabis smoking is associated with dry mouth and periodontal complications that can affect long-term implant health.
  • CBD products can interact with medications and are not automatically irrelevant because they are nonintoxicating.

Evidence and decision snapshot

Cannabis Use, Anesthesia, and Dental Implant Surgery decision snapshot
QuestionEstablished rolePossible valueImportant limitation
Acute intoxicationElective treatment should be postponed when judgment is impaired.Protects consent and perioperative safety.Duration varies by dose, product, and route.
Recent smokingASRA guidance recommends at least a two-hour delay for elective surgery.Reduces period of highest observed cardiovascular concern.A longer delay may be appropriate based on clinical status.
Chronic heavy useRequires preoperative disclosure and individualized anesthesia planning.Allows dose and pain planning.Evidence suggests higher anesthetic and postoperative analgesic needs in some users.
CBD or ediblesStill relevant to medication review.Avoids smoke exposure.Onset, duration, labeling, sedation, and drug interactions can be unpredictable.

Why disclosure is a safety issue

Cannabis use is common and may be recreational, medicinal, or self-directed. The clinician needs the product, route, frequency, amount, and last use. The purpose is not judgment or law enforcement; it is to avoid preventable anesthesia, cardiovascular, airway, consent, and medication problems.

Patients should also disclose alcohol, opioids, benzodiazepines, sleep medications, stimulants, and other substances. Combined effects can be more important than cannabis alone.

Cardiovascular and airway effects

Smoking cannabis can raise heart rate and blood pressure during the first one to two hours and may increase perioperative myocardial infarction risk during that period. Inhaled cannabis can irritate airways and may contribute to bronchospasm, cough, or respiratory events. These issues are especially relevant for IV sedation or general anesthesia.

ASRA recommends delaying elective surgery for a minimum of two hours after cannabis smoking. This is a minimum, not a guarantee of normal function. Symptoms, heavy use, coexisting heart or lung disease, and the planned anesthetic may justify a longer delay or rescheduling.

Anesthetic dose and postoperative pain

Some oral-surgery studies report that frequent cannabis users require more propofol or other IV anesthetic medication. Perioperative guidelines also note evidence of increased postoperative pain and opioid needs among users. Individual response varies, and clinicians should not simply increase medication without monitoring.

Multimodal pain control, local anesthesia, and careful follow-up are appropriate. Cannabis should not be presented as a proven substitute for standard acute postoperative analgesia.

Oral and peri-implant health

Cannabis smoking is associated with xerostomia, periodontal disease, mucosal changes, and caries risk, although tobacco and other confounders are common. Dry mouth and frequent cariogenic snacking can damage remaining teeth and complicate maintenance.

Before implant surgery, periodontal inflammation and oral hygiene should be stabilized. Long-term users may need dry-mouth prevention and closer maintenance.

CBD, edibles, and product variability

Edibles have delayed onset and longer duration, which can lead to unrecognized impairment. Concentrates may deliver high THC doses. CBD can affect hepatic drug-metabolizing enzymes and may interact with anticoagulants, antiseizure drugs, sedatives, and other medications. Product labeling is not always reliable.

The safe approach is disclosure and individualized planning, not a universal cutoff for every product. Patients should follow the anesthesia provider's preoperative instructions.

Frequently asked questions

Can I use cannabis the night before surgery?

Tell the anesthesia team. The answer depends on route, amount, frequency, and planned sedation. Do not arrive intoxicated.

Why must surgery be delayed after smoking?

Heart rate, blood pressure, airway effects, and acute myocardial risk are most concerning shortly after smoking. ASRA recommends at least a two-hour delay for elective surgery.

Does CBD matter?

Yes. It may cause sedation or interact with other drugs even without THC intoxication.

Will I need more anesthesia?

Some frequent users do, but dose should be titrated by trained clinicians with monitoring rather than assumed.

Does cannabis affect implants long term?

Smoking-related dry mouth and periodontal disease can increase maintenance concerns. Direct implant-specific evidence is still developing.

Questions to discuss with your implant team

  • What product, route, frequency, amount, and last use apply?
  • Is there current intoxication or impaired consent?
  • Will local anesthesia, oral sedation, IV sedation, or general anesthesia be used?
  • Are heart, lung, sleep-apnea, or medication-interaction risks present?
  • What transportation and postoperative monitoring are arranged?

What this means for patients: Cannabis use should be disclosed before implant surgery. Do not arrive intoxicated. Route, timing, frequency, cardiovascular and airway effects, and planned sedation all matter. Honest screening lets the team protect consent, anesthesia safety, and postoperative pain control.

Selected references

  1. Shah S, Schwenk ES, Sondekoppam RV, et al. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med. 2023;48(3):97-117. doi:10.1136/rapm-2022-104013. View source.
  2. American Dental Association. Cannabis: Oral Health Effects. ADA Oral Health Topics. Accessed July 28, 2026. View source.
  3. ASRA Pain Medicine. All Patients Should Be Screened for Cannabis Use Before Surgery. January 3, 2023. View source.
  4. Ripperger T, et al. Cannabis use and intravenous anesthetic requirements during ambulatory oral surgery. J Oral Maxillofac Surg. 2023.
  5. American Society of Anesthesiologists. Cannabis and surgery patient-safety resources. Accessed July 28, 2026.